The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and ...

Sanofi’s innovation hub, which employs 2,500 people, is based in Cambridge, Massachusetts. Swiftwater, Pennsylvania contains the company’s vaccine production sites, whilst Framingham ...

At least seven human remains found across Connecticut, Rhode Island and Massachusetts between March and April warrant "review and investigation," according to Pennsylvania-based criminal defense ...

The FDA cites contamination at Massachusetts plant where Sanofi makes ingredients used to produce various ... pharmaceutical ingredients at their Genzyme manufacturing plant in Framingham, ...

Agency cites contamination at Massachusetts plant where company ... ingredients at their Genzyme manufacturing plant in Framingham, Massachusetts. On Jan. 15, 2025, a warning letter was sent to Sanofi ...

(HealthDay News) — The US Food and Drug Administration (FDA) has warned Sanofi about significant ... their Genzyme manufacturing plant in Framingham, Massachusetts. On January 15, a warning ...

The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant ... their Genzyme manufacturing plant in Framingham, Massachusetts. On Jan. 15, 2025, a warning ...

The agency’s newly issued letter to Sanofi amends one sent in December 2024, and stems from inspections at its Massachusetts drug manufacturing ... acts as a company drug manufacturing facility, in ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham. Biggest Boston ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...